Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q1 EPS of ($0.63), in-line with the analyst estimate of ($0.63).

As of March 31, 2022, Syndax had cash, cash equivalents and short-term investments of $397.9 million and 59.0 million shares and share equivalents issued and outstanding. This includes 4.0 million pre-funded warrants.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.